{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001047","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2023-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.507187+00:00","generated_at":"2026-06-13T14:45:14.525110+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aldeyra reports positive Phase 2 data for ADX-2191 in retinitis pigmentosa","bullets":["Statistically significant improvement in best corrected visual acuity (P<0.0001) and low-light visual acuity (P=0.0001).","Perimetry showed improved macular sensitivity (P<0.0001) and dark-adapted peripheral sensitivity (P<0.0001).","Electroretinography time to response improved (P=0.02); no safety concerns identified.","All 8 patients completed trial; ADX-2191 well tolerated with no serious adverse events.","Company plans to discuss Phase 2/3 trial design with regulatory authorities."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001047","json":"https://secwatch.observer/filing/0001157523-23-001047.json","markdown":"https://secwatch.observer/filing/0001157523-23-001047.md","text":"https://secwatch.observer/filing/0001157523-23-001047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000115752323001047/0001157523-23-001047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000115752323001047/a53436990.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:45:14.525110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}